Answers are grounded in this paper and cite their sources.
BACKGROUND: Methoxy polyethylene glycol-epoetin beta is a continuous erythropoietin receptor activator (CERA) that provides stable control of blood hemoglobin levels at extended administration intervals in patients with chronic kidney disease. The purpose of this single-center case study is to assess whether patients on peritoneal dialysis (PD) can be successfully switched from previous darbepoetin alfa treatment to CERA with extended dose intervals. METHODS: Selective PD patients receiving regular darbepoetin alfa therapy were switched to monthly or bimonthly CERA injections. Data of blood biochemical tests and dialysis adequacy before and after 6 months of CERA treatment were analyzed to evaluate the effect on hemoglobin maintenance. RESULTS: Fifteen PD patients (mean age: 50.4 years; men: 9, women: 6) were enrolled for this study. Mean baseline and evaluation-period hemoglobin levels were similar (10.2 ± 0.66 vs. 10.1 ± 1.35 g/dL, P = 0.450). No change in blood hemoglobin levels and biochemical or dialysis adequacy parameters before and after 6 months of CERA treatment was noted. The dosages of darbepoetin alfa (1.51 μg/kg/month) and CERA (1.59 μg/kg/month) used for erythropoiesis were similar. The average monthly cost of darbepoetin alfa (NT$ 4337 ± 1069) and CERA (NT$ 4775 ± 728) also showed no significant difference. CONCLUSIONS: PD patients receiving regular darbepoetin alfa treatment could be safely switched to CERA injection of similar dosage levels at extended dose intervals. Large-scale studies are needed to confirm our observation.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: